The clinical applications of fluorouracil in ophthalmic practice

被引:63
作者
Abraham, Lekha M.
Selva, Dinesh
Casson, Robert
Leibovitch, Igal
机构
[1] Univ Adelaide, Royal Adelaide Hosp, Dept Ophthalmol & Visual Sci, Glaucoma Serv,S Australian Inst Ophthalmol, Adelaide, SA 5000, Australia
[2] Univ Adelaide, Royal Adelaide Hosp, Oculoplast & Orbital Unit, S Australian Inst Ophthalmol, Adelaide, SA 5000, Australia
[3] Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia
[4] Univ Adelaide, Dept Surg, Adelaide, SA 5001, Australia
[5] Tel Aviv Univ, Tel Aviv Med Ctr, Oculoplast & Orbital Div, Dept Ophthalmol, IL-69978 Tel Aviv, Israel
关键词
D O I
10.2165/00003495-200767020-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fluorouracil (5-fluorouracil, 5-FU) is a pyrimidine analogue that was originally known for its widespread use as an anticancer drug. The ability of 5-FU to reduce fibroblastic proliferation and subsequent scarring has made it an important adjunct in ocular and periorbital surgeries. It is used in primary glaucoma filtering surgeries and in reviving failing filtering blebs, in dacryocystorhinostomy, pterygium surgery, and in vitreoretinal surgery to prevent proliferative vitreoretinopathy. In addition, 5-FU is also gaining recognition in the treatment and surgical management of ocular surface malignancies like ocular surface squamous neoplasia; however, the specific action of the drug on highly proliferating cells limits its use in primary acquired melanosis of the conjunctiva. When applied topically, this drug has a low rate of sight-threatening adverse effects, is inexpensive, and is easy to administer, making it an important tool in enhancing the success rate in ophthalmic surgery and in reducing the recurrence of ocular surface neoplasia.
引用
收藏
页码:237 / 255
页数:19
相关论文
共 130 条
[71]  
Malet-Martino M., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P267
[72]   Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma: 1 Intraocular pressure control and complications [J].
Membrey, WL ;
Poinoosawmy, DP ;
Bunce, C ;
Hitchings, RA .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2000, 84 (06) :586-590
[73]   Effects of varying 5-fluorouracil exposure duration on Tenon's capsule fibroblasts [J].
Merriman, MB ;
Mora, JS ;
Beaumont, BW ;
Merrilees, MJ .
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2001, 29 (04) :248-252
[74]   Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil [J].
Midena, E ;
Angeli, CD ;
Valenti, M ;
de Belvis, V ;
Boccato, P .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2000, 84 (03) :268-272
[75]   Conjunctival squamous cell carcinoma treated with topical 5-fluorouracil [J].
Midena, E ;
Boccato, P ;
Angeli, CD .
ARCHIVES OF OPHTHALMOLOGY, 1997, 115 (12) :1600-1601
[76]   Intraoperative 5-fluorouracil application during primary trabeculectomy in Nigeria: a comparative study [J].
Mielke, C ;
Dawda, VK ;
Anand, N .
EYE, 2003, 17 (07) :829-834
[77]   Comparative pharmacology of oral fluoropyrimidines:: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation [J].
Milano, G ;
Ferrero, JM ;
François, E .
BRITISH JOURNAL OF CANCER, 2004, 91 (04) :613-617
[78]   Incidence of delayed onset infection after trabeculectomy with adjunctive mitomycin C or 5-fluorouracil treatment [J].
Mochizuki, K ;
Jikihara, S ;
Ando, Y ;
Hori, N ;
Yamamoto, T ;
Kitazawa, Y .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1997, 81 (10) :877-883
[79]   Trabeculectomy with intraoperative sponge 5-fluorouracil [J].
Mora, JS ;
Nguyen, N ;
Iwach, AG ;
Gaffney, MM ;
Hetherington, J ;
Hoskins, HD ;
Wong, PC ;
Tran, H ;
Dickens, CJ .
OPHTHALMOLOGY, 1996, 103 (06) :963-970
[80]  
OCCLESTON NL, 1994, INVEST OPHTH VIS SCI, V35, P3681